GlassScriptPhysician profile
Richard A Dougherty
NPI 1629068515
$18,318.05
in general payments reported to CMS, 2019-2025
49 companies · $2,291 in 2025
The $2,291 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,226 · 2020: $2,744 · 2021: $2,917 · 2022: $2,247 · 2023: $2,936 · 2024: $2,958 · 2025: $2,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,901 · Education: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,900.62 |
| Education | $283.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,463.58 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $2,249.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,573.35 | 2019-2025 | Jardiance, Synjardy |
| Amgen INC. | $1,320.10 | 2019-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $1,209.62 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $1,198.02 | 2019-2024 | Xarelto |
| Abbvie INC. | $1,016.70 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Pfizer INC. | $811.10 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $674.03 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $615.34 | 2019-2022 | |
| Astellas Pharma US INC | $603.86 | 2019-2024 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $536.59 | 2019-2025 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $456.49 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $384.66 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $338.85 | 2023-2025 | Gemtesa |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Dougherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.